

Claims

- [c1] 1.A composition including an effective amount of the polypeptide EEIIMI and a fibrinolytic agent to induce the desired level of fibrinolytic activity without causing hemorrhage.
- [c2] 2.The composition according to Claim 1, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.
- [c3] 3.A composition including an effective amount of fibrinolytic agent and a sufficient amount of LRP antibodies to inhibit vasoactivity induced by the fibrinolytic agent used.
- [c4] 4.The composition according to Claim 3, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.
- [c5] 5.A composition including an effective amount of fibrinolytic agent and a sufficient amount of LRP antagonist to inhibit vasoactivity induced by the fibrinolytic agent used.
- [c6] 6.The composition according to Claim 5, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.
- [c7] 7. A method of enhancing the fibrinolytic activity of a fibrinolytic agent by administering an effective amount of the polypeptide EEIIMI and a fibrinolytic agent to induce the desired level of fibrinolytic activity without causing hemorrhage.
- [c8] 8.The method according to Claim 7, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase

complex, anistreplase, or a streptokinase derivative.

- [c9] 9.A method of prolonging the half-life of a fibrinolytic agent by administering an effective amount of anti-LRP antibodies and a fibrinolytic agent to induce the desired level of fibrinolytic activity without causing hemorrhage.
- [c10] 10.The method according to Claim 9, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA-derivatives, reteplase, lanoteplase, TNK-rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.